Invivyd, Inc. (NASDAQ:IVVD) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 179.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 117,973 shares of the company’s stock after purchasing an additional 75,780 shares during the period. Barclays PLC’s holdings in Invivyd were worth $120,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in IVVD. Duquesne Family Office LLC acquired a new position in shares of Invivyd in the 2nd quarter valued at approximately $629,000. Acadian Asset Management LLC raised its position in shares of Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after purchasing an additional 474,301 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Invivyd in the 2nd quarter valued at approximately $421,000. Bank of New York Mellon Corp acquired a new position in shares of Invivyd in the 2nd quarter valued at approximately $263,000. Finally, Dimension Capital Management LLC raised its position in shares of Invivyd by 243.3% in the 2nd quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock valued at $209,000 after purchasing an additional 134,571 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares of the company’s stock, valued at $2,768,228.19. This trade represents a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 816,466 shares of company stock valued at $423,214 over the last three months. Company insiders own 17.90% of the company’s stock.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.46 on Thursday. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The business’s fifty day moving average price is $0.65 and its two-hundred day moving average price is $0.92. The firm has a market capitalization of $55.20 million, a PE ratio of -0.24 and a beta of 0.64.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on IVVD shares. HC Wainwright dropped their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Morgan Stanley dropped their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday, November 21st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.